Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Depreciation and Depletion: 2013-2024

Historic Depreciation and Depletion for Aclaris Therapeutics (ACRS) over the last 12 years, with Dec 2024 value amounting to $700,000.

  • Aclaris Therapeutics' Depreciation and Depletion fell 50.00% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $400,000, marking a year-over-year decrease of 50.00%. This contributed to the annual value of $700,000 for FY2024, which is 12.50% down from last year.
  • As of FY2024, Aclaris Therapeutics' Depreciation and Depletion stood at $700,000, which was down 12.50% from $800,000 recorded in FY2023.
  • Aclaris Therapeutics' Depreciation and Depletion's 5-year high stood at $1.1 million during FY2020, with a 5-year trough of $700,000 in FY2022.
  • For the 3-year period, Aclaris Therapeutics' Depreciation and Depletion averaged around $733,333, with its median value being $700,000 (2024).
  • As far as peak fluctuations go, Aclaris Therapeutics' Depreciation and Depletion dropped by 27.27% in 2021, and later rose by 14.29% in 2023.
  • Aclaris Therapeutics' Depreciation and Depletion (Yearly) stood at $1.1 million in 2020, then declined by 27.27% to $800,000 in 2021, then declined by 12.50% to $700,000 in 2022, then climbed by 14.29% to $800,000 in 2023, then decreased by 12.50% to $700,000 in 2024.